← Back to Calendar
Live Company Data
NMS
Updated
just now
· Data: FMP
Current Price
$26.41
+154.43%
+$16.03 today
Day: $25.95 – $26.78
52-Week Range
Current price is at 82% of 52-week range
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Dermatomyositis (DM) — inflammatory myopathy
Key Notes
NDA accepted with Priority Review. PDUFA Q3 2026 with launch expected end of September 2026 (company guidance, confirmed March 3, 2026). TYK2/JAK1 inhibitor. Dermatomyositis is a rare autoimmune inflammatory myopathy with no approved targeted therapies. Phase 3 clinical program supported the NDA. Brepocitinib is also in Phase 3 for non-infectious uveitis. Would be the first FDA-approved targeted therapy specifically for dermatomyositis.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.